Lesli A. Kiedrowski

2.9k total citations · 1 hit paper
48 papers, 1.4k citations indexed

About

Lesli A. Kiedrowski is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lesli A. Kiedrowski has authored 48 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Cancer Research, 23 papers in Oncology and 22 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lesli A. Kiedrowski's work include Cancer Genomics and Diagnostics (32 papers), Lung Cancer Treatments and Mutations (14 papers) and Genetic factors in colorectal cancer (11 papers). Lesli A. Kiedrowski is often cited by papers focused on Cancer Genomics and Diagnostics (32 papers), Lung Cancer Treatments and Mutations (14 papers) and Genetic factors in colorectal cancer (11 papers). Lesli A. Kiedrowski collaborates with scholars based in United States, Canada and Italy. Lesli A. Kiedrowski's co-authors include Richard B. Lanman, Rebecca J. Nagy, Kimberly C. Banks, Jochen K. Lennerz, Stephen R. Fairclough, Justin I. Odegaard, W. Marston Linehan, Samuel J. Klempner, Justin F. Gainor and Rebecca S. Heist and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Blood.

In The Last Decade

Lesli A. Kiedrowski

44 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation

2021 302 citations Noritaka Tanaka, W. Marston Linehan et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Lesli A. Kiedrowski

Since Specialization

Citations

This map shows the geographic impact of Lesli A. Kiedrowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lesli A. Kiedrowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lesli A. Kiedrowski more than expected).

Fields of papers citing papers by Lesli A. Kiedrowski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lesli A. Kiedrowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lesli A. Kiedrowski. The network helps show where Lesli A. Kiedrowski may publish in the future.

Co-authorship network of co-authors of Lesli A. Kiedrowski

This figure shows the co-authorship network connecting the top 25 collaborators of Lesli A. Kiedrowski. A scholar is included among the top collaborators of Lesli A. Kiedrowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lesli A. Kiedrowski. Lesli A. Kiedrowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis 2023 ·Therapeutic Advances in Medical Oncology ·Arielle J. Medford, Lauren Oshry, Bariş Boyraz, Lesli A. Kiedrowski, (unknown), (unknown), Charles S. Dai, Tasos Gogakos, (unknown), Rachel O. Abelman, (unknown), Jochen K. Lennerz, Laura M. Spring, Beverly Moy, Leif W. Ellisen, Aditya Bardia	5
2	The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib 2023 ·Clinical Cancer Research ·Timothy J. Brown, Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, (unknown), Mark H. O’Hara, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, Erica L. Carpenter, Katherine L. Nathanson, Susan M. Domchek, Kim A. Reiss	10
3	Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes 2023 ·JCO Precision Oncology ·Pashtoon Murtaza Kasi, (unknown), Jiemin Liao, Jason S. Starr, Pedro C. Barata, Samuel J. Klempner, David R. Gandara, Ardaman Shergill, Luciana Madeira da Silva, Caroline Weipert, Nicole Zhang, Christopher R. Pretz, Aaron Hardin, Lesli A. Kiedrowski, Justin I. Odegaard	8
4	The identification of reversion mutations in patients with advanced pancreatic cancer and germline or somatic BRCA or PALB2 variants who were treated with maintenance rucaparib. 2023 ·Journal of Clinical Oncology ·Timothy J. Brown, Arielle Yablonovitch, Jennifer Yen, Lesli A. Kiedrowski, Erica L. Carpenter, Katherine L. Nathanson, Susan M. Domchek, (unknown)	1
5	ESR1 mutational landscape and impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer. 2023 ·Journal of Clinical Oncology ·Arielle J. Medford, Ignaty Leshchiner, (unknown), Lesli A. Kiedrowski, Andrzej Niemierko, (unknown), Seth A. Wander, Laura M. Spring, Neelima Vidula, Charles S. Dai, Steven J. Isakoff, Lorenzo Gerratana, Ami N. Shah, Andrew A. Davis, Massimo Cristofanilli, Beverly Moy, Leif W. Ellisen, Gad Getz, Aditya Bardia	1
6	Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis 2023 ·JTO Clinical and Research Reports ·Ibiayi Dagogo‐Jack, Lesli A. Kiedrowski, Rebecca S. Heist, W. Marston Linehan, Catherine B. Meador, (unknown), Andrew Do, Jennifer Peterson, Lecia V. Sequist, Justin F. Gainor, Jochen K. Lennerz, Subba R. Digumarthy	9
7	Plasma-only multiomic minimal residual disease (MRD) testing in 2,000 consecutive patients with colorectal cancer (CRC). 2023 ·Journal of Clinical Oncology ·Katrina S. Pedersen, Benjamin Tan, (unknown), Lesli A. Kiedrowski, (unknown)	2
8	Molecular heterogeneity and co-altered genes in MET-amplified ALK-positive lung cancer: Implications for MET targeted therapy 2023 ·Lung Cancer ·Ibiayi Dagogo‐Jack, Lesli A. Kiedrowski, Jochen K. Lennerz	2
9	Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers 2022 ·Nature ·Yoshihisa Kobayashi, (unknown), Jiaqi Li, Kristin S. Price, Lesli A. Kiedrowski, (unknown), Aaron Hardin, Zihan Wei, Fangxin Hong, Magda Bahcall, Prafulla C. Gokhale, Pasi A. Jänne	31
10	The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer 2022 ·Therapeutic Advances in Medical Oncology ·Doreen A. Ezeife, Eldon Spackman, Rosalyn A. Juergens, Janessa Laskin, Jason Agulnik, Desirée Hao, Scott A. Laurie, Jennifer Law, Lisa W. Le, Lesli A. Kiedrowski, Barbara Melosky, Frances A. Shepherd, Victor Cohen, Paul Wheatley‐Price, R Vandermeer, Janice J.N. Li, Roxanne Fernandes, (unknown), Richard B. Lanman, Natasha B. Leighl	27
11	Prevalence of ARID1A Mutations in Cell-Free Circulating Tumor DNA in a Cohort of 71,301 Patients and Association with Driver Co-Alterations 2022 ·Cancers ·Razelle Kurzrock, Charu Aggarwal, Caroline Weipert, Lesli A. Kiedrowski, Jonathan W. Riess, Heinz‐Josef Lenz, David R. Gandara	10
12	Use of on-therapy ctDNA monitoring in a patient with KIF5B-RET fusion positive advanced non-small cell lung cancer: a case report 2022 ·Translational Lung Cancer Research ·Vincent Yeung, Chul Kim, Lesli A. Kiedrowski, Stephen V. Liu, Joshua E. Reuss	4
13	Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation breakdown → 2021 ·Cancer Discovery ·Noritaka Tanaka, W. Marston Linehan, Chendi Li, Meagan B. Ryan, Junbing Zhang, Lesli A. Kiedrowski, Alexa Michel, Mohammed U. Syed, (unknown), Mustafa Sakhi, Islam Baiev, Dejan Juric, Justin F. Gainor, Samuel J. Klempner, Jochen K. Lennerz, Giulia Siravegna, Liron Bar‐Peled, Aaron N. Hata, Rebecca S. Heist, Ryan B. Corcoran	302
14	Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma 2021 ·Clinical Cancer Research ·Zeynep Büşra Zengin, Caroline Weipert, Nicholas Salgia, Nazlı Dizman, Joann Hsu, Luís Meza, Alex Chehrazi‐Raffle, Ramya Muddasani, Sabrina Salgia, Jasnoor Malhotra, Neal Shiv Chawla, Errol J. Philip, Lesli A. Kiedrowski, Benjamin L. Maughan, Nityam Rathi, (unknown), Toni K. Choueiri, Neeraj Agarwal, Sumanta K. Pal	18
15	Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy 2021 ·JCO Precision Oncology ·Jeffrey C. Thompson, Erica L. Carpenter, (unknown), (unknown), Austin L. Chien, Katie Quinn, Carin R. Espenschied, Allysia J. Mak, Lesli A. Kiedrowski, Martina I. Lefterova, Rebecca J. Nagy, Sharyn I. Katz, Stephanie S. Yee, Taylor A. Black, Aditi P. Singh, Christine Ciunci, Joshua Bauml, Roger B. Cohen, Corey J. Langer, Charu Aggarwal	62
16	1195P The value of detecting resistance through liquid biopsy 2020 ·Annals of Oncology ·Scott A. Laurie, Jason Agulnik, Desirée Hao, Rosalyn A. Juergens, Doreen A. Ezeife, (unknown), Lisa W. Le, Lesli A. Kiedrowski, Frances A. Shepherd, V. Cohen, B. Melosky, R Vandermeer, Paul Wheatley‐Price, Richard B. Lanman, Natasha B. Leighl, Janessa Laskin	1
17	Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma 2019 ·Clinical Cancer Research ·Steven B. Maron, Leah M. Chase, Samantha Lomnicki, Sara Kochanny, Kelly L. Moore, Smita S. Joshi, (unknown), (unknown), Lesli A. Kiedrowski, Rebecca J. Nagy, Richard B. Lanman, Seung Tae Kim, Jeeyun Lee, Daniel V.T. Catenacci	147
18	Clinical Utilization Pattern of Liquid Biopsies (LB) to Detect Actionable Driver Mutations, Guide Treatment Decisions and Monitor Disease Burden During Treatment of 33 Metastatic Colorectal Cancer (mCRC) Patients (pts) at a Fox Chase Cancer Center GI Oncology Subspecialty Clinic 2019 ·Frontiers in Oncology ·Pooja Ghatalia, (unknown), Arthur Winer, Jiangtao Gou, Lesli A. Kiedrowski, Michael Slifker, (unknown), (unknown), (unknown), (unknown), Asya Varshavsky, Yang Liu, Eric A. Ross, Wafik S. El‐Deiry	12
19	Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies 2018 ·Clinical Cancer Research ·Justin I. Odegaard, John J. Vincent, Stefanie Mortimer, James V. Vowles, Bryan C. Ulrich, Kimberly C. Banks, Stephen R. Fairclough, Oliver A. Zill, Marcin Sikora, Reza Bayat Mokhtari, Diana Abdueva, Rebecca J. Nagy, Christine E. Lee, Lesli A. Kiedrowski, Cloud P. Paweletz, Helmy Eltoukhy, Richard B. Lanman, Darya Chudova, AmirAli Talasaz	283
20	Refining the structure and content of clinical genomic reports 2014 ·American Journal of Medical Genetics Part C Seminars in Medical Genetics ·Michael O. Dorschner, Laura M. Amendola, Brian H. Shirts, Lesli A. Kiedrowski, Joseph S Salama, Allan Gordon, Stephanie M. Fullerton, Peter Tarczy‐Hornoch, Peter H. Byers, Gail P. Jarvik	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact